Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

Size: px
Start display at page:

Download "Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors"

Transcription

1 Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO) Barcelona, Spain

2 Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies Tumors arising from enterochromaffin cells located in neuroendocrine tissue throughout the body 1 NETs can be functional or nonfunctional and include a heterogeneous group of neoplasms 2,3 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) 3 Islet cell tumors 2 Typical/atypical/poorly differentiated lung carcinoid 2 Small cell carcinoma of the lung 2,3 Pheochromocytoma/paraganglioma 2,3 Medullary thyroid carcinoma Merkel cell carcinoma 2,3 Kidney, bladder, breast, prostate, thymus 1. Caplin ME, et al. Lancet. 1998;352(9130): ; 2. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors V2.2016; 3. Modlin IM, et al. Gastroenterology. 2005;128(6):

3 Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies Tumors arising from enterochromaffin cells located in neuroendocrine tissue throughout the body 1 N NETs can be functional or nonfunctional and include a heterogeneous group of neoplasms 2,3 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) 3 E Islet cell tumors 2 Typical/atypical/poorly differentiated lung carcinoid 2 Small cell carcinoma of the lung 2,3 Pheochromocytoma/paraganglioma 2,3 Medullary thyroid carcinoma T EAR VERYWHERE UMORS Merkel cell carcinoma 2,3 Kidney, bladder, breast, prostate, thymus 1. Caplin ME, et al. Lancet. 1998;352(9130): ; 2. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors V2.2016; 3. Modlin IM, et al. Gastroenterology. 2005;128(6):

4 The Increasing Incidence of NET Lung and bronchus Incidence per Year Rectum Small intestine Pancreas Stomach Cecum Colon Appendix Annual age-adjusted incidence of NETs in the US population by anatomic location Using regression analysis, it is estimated that the incidence in 2013 could be nearly 8 per Yao JC, et al. J Clin Oncol. 2008;26(18):

5 The Gastrointestinal Tract (GI) Is the Most Common Primary Location of NET (US SEER Data) Other/ unknown Lung 15% 27% Digestive system 58% Percent distribution (%) 17.2 Rectum 13.4 Jejunum/ileum 6.4 Pancreas 6.0 Stomach 4.0 Colon 3.8 Duodenum 3.2 Cecum 3.0 Appendix 0.8 Liver Yao JC, et al. J Clin Oncol. 2008;26(18):

6 NETs Are the Second Most Prevalent Type of GI Malignancy times more prevalent than pancreatic cancer Colorectal 1 GEP-NET 2 Stomach 1 Pancreas 1 Esophagus 1 Hepatobiliary 1 Prevalence in SEER Database 1. National Cancer Institute: SEER Cancer Statistics Review, Accessed: September 8, Modlin IM, et al. Cancer. 2003;97(4):

7 Complex Disease

8 Constellation of Symptoms Makes a Differential Diagnosis Difficult Nonspecific symptoms are common to multiple diagnoses Menopause Food allergy Neurosis NETs Symptoms Sweating Flushing Diarrhea Intermittent abdominal pain Bronchoconstriction GI bleeding Cardiac disease Functional bowel disease Irritable bowel syndrome Alcoholism Asthma Thyrotoxicosis Anxiety Estimated time to diagnosis: 5 to 7 years 3 Peptic ulcer 1. Vinik A, et al. Dig Dis Sci. 1989;34(3)(suppl):14S-27S. 2. Toth-Fejel S, et al. Am J Surg. 2004;187(5): Modlin IM, et al. J Natl Cancer Inst. 2008;100(18):

9 NETs Are Often Advanced at the Time of Diagnosis Carcinoids M 1 at Dx SV 5 and M 1 Small intestine 70% 55% Colon 71% 20% Appendix 10% 34% Rectum 15% 30% Pancreatic NETs 50%-60% 30%-50% Median survival (years) Local 18.5 Well and moderately differentiated Regional 9.25 Metastatic 2.75 Poorly differentiated metastatic Yao JC, et al. J Clin Oncol. 2008;26(18): Soga J. Cancer. 2005;104(6): Alexiev BA, et al. Diagn Pathol. 2007;2: Modlin IM, et al. Lancet. 2008;9(1):61-72.

10 Correlation of Primary Tumor Site With Survival Known prognostic factors include: Distant metastases Location of primary tumor Extent of disease Tumor stage Degree of differentiation/ proliferative index Tumor grade Patient age Survival probability Colon Lung Pancreas Rectum Small bowel Performance status Time, months 65% of patients with advanced NETs will not be alive in 5 years Yao JC, et al. J Clin Oncol. 2008;26(18):

11 Prognostic Value of Ki67 <2% 15% 75% Ekeblad S, et al. Clin Cancer Res. 2008;14(23): Vilar E, et al. Endocr Relat Cancer. 2007;14(2): Grade Mitotic count (10 HPF) Ki-67 index (%) G1 <2 2 G G3 >20 >20 Pape UF, et al. Endocr Relat Cancer. 2008;15(4): Scarpa A, et al. Mod Pathol. 2010;23(6):

12 But Differentiation Is Also Important Well- and moderately-differentiated histology Histology Poorly differentiated histology Yao JC, et al. J Clin Oncol. 2008;26(18):

13 High Complexity for NETs Classification Differentiation Grade Mitotic count Ki67 index Traditional ENETS; WHO Well differentiated Poorly differentiated Low grade (G1) Intermediate grade (G2) High grade (G3) <2 per 10 high power fields (HPFs) 2% Carcinoid, islet cell, pancreatic (neuro)endocrine tumor 2-20 per 10 HPFs 3%-20% Carcinoid, islet cell, pancreatic (neuro)endocrine tumor >20 per 10 HPFs >20% Well differentiated Small cell carcinoma Large cell neuroendocrine carcinoma Poorly differentiated Grade (ENETS) Low (G1) Intermediate (G2) High (G3) Ki67 index (%) >20 Anatomic imaging Funational imaging Octreoscan SPECT or SSTR PET-positive More rapid growth on serial imaging FDG PET-positive Prognosis Indolent (slowly growing) Aggressive Neuroendocrine tumor; grade 1 Neuroendocrine tumor; grade 2 Neuroendocrine tumor; grade 3, small cell Neuroendocrine tumor; grade 3, large cell Bosman FT, eds. WHO Classification of Tumours of the Digestive System. 4 th Ed. Lyon, France: The International Agency for Research on Cancer; Rindi G, et al. Virchows Arch. 2006;449(4): Rindi G, et al. Virchows Arch. 2007;451(4) Jensen RT, et al. Neuroendocrinology. 2006;84(3):

14 Best Treatment Option Based on MDT Evaluation Pathologist Surgeon Every one helps Nuclear Medicine Best treatment option Oncologist Endocrinologist Gastroenterologist

15 Factors Influencing the Therapeutic Decision in NETs Type of NET (pancreatic vs GI) Resectability Patient performance status and comorbidities Uptake on somatostatin receptor scintigraphy TNM stage and grade (G1/G2 vs G3) Functioning vs nonfunctioning tumor Availability of different therapeutic modalities Patient preference and convenience

16 Integrating Grade and Tumor Burden High Treatment goals: Tumor control and QoL Advanced, unresectable, well- to moderately- differentiated NETs: Primary treatment goals Tumor response/control & QoL Tumor response/control Rapid Tumor Response Tumor burden QoL & tumor control Tumor control & QoL Tumor control/ response Low QoL & tumor control Tumor control & QoL Tumor control & QoL Low Tumor aggressiveness (eg, Ki67) Moderate (up to Ki67 = 20%)

17 Progressive Increase in Survival Overall Survival, months OS NR OS NR OS NR 44 months 33 months OS NR OS NR OS PFS Arnold R, et al. J Clin Oncol. 2013;31(suppl): Abstract Caplin M, et al. N Engl J Med. 2014;371(3): Pavel M, et al. Ann Oncol. 21(suppl 8): Abstract LBA-8. Pavel ME, et al. J Clin Oncol. 2015;33(suppl): Abstract Vinik A, et al. J Clin Oncol. 2012;30(15S): Abstract Yao JC, et al. Ann Oncol. 2015;26(suppl 6): Abstract LBA-5. Strosberg J, et al. Eur J Cancer. 2015;51(Suppl 3): Abstract LBA-6.

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic

More information

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS

More information

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND

More information

Selection of Appropriate Treatment

Selection of Appropriate Treatment Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies

More information

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body

More information

Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience

Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience RESEARCH ARTICLE Editorial Process: Submission:00/00/0000 Acceptance:00/00/0000 : A 15-Year Single Center Experience Abdullah Sakin 1 *, Makbule Tambas 2, Saban Secmeler 3, Orçun Can 3, Serdar Arici 3,

More information

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine

More information

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs. GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March

More information

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy

More information

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

MEDICAL MANAGEMENT OF METASTATIC GEP-NET MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine

More information

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm

More information

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different

More information

An Overview of NETS. Richard R.P. Warner M.D

An Overview of NETS. Richard R.P. Warner M.D An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first

More information

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from

More information

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions MONDAY TEACHING SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN)

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.

More information

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID Manoop S. Bhutani, MD, FASGE, FACG, FACP, AGAF, Doctor Honoris Causa Professor of Medicine Eminent Scientist of the Year 2008, World

More information

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine

More information

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts

More information

Gastrinoma: Medical Management. Haley Gallup

Gastrinoma: Medical Management. Haley Gallup Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical

More information

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some

More information

NET und NEC. Endoscopic and oncologic therapy

NET und NEC. Endoscopic and oncologic therapy NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation

More information

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,

More information

Carcinoembryonic Antigen

Carcinoembryonic Antigen Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring

More information

CRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines

CRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines CRITICAL ANALYSIS OF NEN GUIDELINES G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines DISCLOSURES NO CONFLICTS OF INTEREST TO DECLARE UPDATED

More information

CEA (CARCINOEMBRYONIC ANTIGEN)

CEA (CARCINOEMBRYONIC ANTIGEN) (CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant

More information

Chibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article

Chibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article Original Article Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile

More information

A New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy

A New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi

More information

Nuevas alternativas en el manejo de TNE avanzados

Nuevas alternativas en el manejo de TNE avanzados Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,

More information

Small cell neuroendocrine carcinoma icd 10

Small cell neuroendocrine carcinoma icd 10 Small cell neuroendocrine carcinoma icd 10 1-10-2017 Free, official coding info for 2018 ICD - 10 -CM C34.90 - includes detailed rules, notes, synonyms, ICD -9- crosswalks, DRG. In most series, LCLC's

More information

Evaluation and Management of Neuroendocrine Tumors

Evaluation and Management of Neuroendocrine Tumors Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017

More information

Somatuline Depot. Somatuline Depot (lanreotide) Description

Somatuline Depot. Somatuline Depot (lanreotide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.27 Subject: Somatuline Depot Page: 1 of 5 Last Review Date: December 8, 2017 Somatuline Depot Description

More information

Prior Authorization Review Panel MCO Policy Submission

Prior Authorization Review Panel MCO Policy Submission Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

Long Term Results in GIST Treatment

Long Term Results in GIST Treatment Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal

More information

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University

More information

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό

More information

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in

More information

Your Medical Details and Treatment Tracker. About You

Your Medical Details and Treatment Tracker. About You This document is intended to help you keep a record of important details that you may need to share with healthcare professionals throughout your Living with Neuroendocrine Tumours (NETs) journey. Take

More information

Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal

Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6

More information

Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter

Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 212067, 5 pages doi:10.1155/2008/212067 Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter

More information

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,

More information

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 18 JUNE 2 28 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E One Hundred Years After Carcinoid : Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases

More information

Imaging of Neuroendocrine Metastases

Imaging of Neuroendocrine Metastases Imaging of Neuroendocrine Metastases Aoife Kilcoyne, Shaunagh McDermott, Colin McCarthy,Manuel Patino, Dushyant Sahani, Michael Blake Abdominal Imaging Division Massachusetts General Hospital Disclosure

More information

Management of Neuroendocrine Tumors

Management of Neuroendocrine Tumors Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of

More information

Neuroendocrine Tumors

Neuroendocrine Tumors Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.

More information

A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands

A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands World J Surg (2018) 42:490 497 DOI 10.1007/s00268-017-4278-y ORIGINAL SCIENTIFIC REPORT A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands

More information

Surgical Therapy of GEP-NET: An Overview

Surgical Therapy of GEP-NET: An Overview Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior

More information

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan Title page Pancreatic neuroendocrine tumors: a single-center 20-year experience with 100 patients A short title: One hundred patients with pancreatic NEN at a single center Contributing Authors: Satoshi

More information

Neuroendocrine Tumors

Neuroendocrine Tumors Neuroendocrine Tumors FCDS Annual Conference Boca Raton Marriott at Boca Center July 28, 2016 Steven Peace, BS, CTR Anatomy and Physiology of the (Neuro)Endocrine System WHO Classification, Tumor Grade

More information

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece SURGERY OF NETS Iakovos N Nomikos MD FACS Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece Epidemiology 5-fold increase in occurrence of NETS over past 30 years

More information

Fast, automated, precise

Fast, automated, precise Thermo Scientific B R A H M S / NSE Immunodiagnostic Assays Fast, automated, precise Neuroendocrine tumor markers on KRYPTOR Systems First and only fully automated CgA assay worldwide Shortest time to

More information

Final stages of colon cancer what to expect

Final stages of colon cancer what to expect Wie of wat? (bakker, DelhaWaar? (postcode, gemeen Final stages of colon cancer what to expect What happens in the last days of life is different for everyone. as changes in breathing, loss of bladder and

More information

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic

More information

Pathology testing and Neuroendocrine tumours (NETs)

Pathology testing and Neuroendocrine tumours (NETs) Pathology testing and Neuroendocrine tumours (NETs) NETs are probably far more common than we think. Most grow so slowly and produce such widely varied and non-specific symptoms, or no symptoms at all,

More information

Appendiceal carcinoid tumours: indications for right hemicolectomy and appendectomy

Appendiceal carcinoid tumours: indications for right hemicolectomy and appendectomy International Surgery Journal Connell JO. Int Surg J. 2016 Aug;3(3):1040-1046 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Review Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20162701

More information

SIRT in the Management of Metastatic Neuroendocrine Tumors

SIRT in the Management of Metastatic Neuroendocrine Tumors SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,

More information

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent

More information

OUTLINE OUTLINE 25/04/2018. Massimo Milione MD, PhD. General Features and Classifications. Ki67 role?

OUTLINE OUTLINE 25/04/2018. Massimo Milione MD, PhD. General Features and Classifications. Ki67 role? 25/04/2018 Massimo Milione MD, PhD Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale Tumori Milano- Italy massimo.milione@istitutotumori.mi.it OUTLINE General Features

More information

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics

More information

Characteristics and treatment of patients with neuroendocrine carcinoma of the gastroesophageal junction: an analysis of 13 cases

Characteristics and treatment of patients with neuroendocrine carcinoma of the gastroesophageal junction: an analysis of 13 cases Original Article Characteristics and treatment of patients with neuroendocrine carcinoma of the gastroesophageal junction: an analysis of 13 cases Yingzhi Qin 1 *, Chao Guo 1 *, Xiaoyan Chang 2, Yeye Chen

More information

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust

More information

WHO e TNM: Importanza della classificazione nell approccio terapeutico

WHO e TNM: Importanza della classificazione nell approccio terapeutico WHO e TNM: Importanza della classificazione nell approccio terapeutico Marco Volante Mauro Papotti Dipartimento di Scienze Cliniche e Biologiche Ospedale San Luigi Orbassano, Torino Rare tumors Heterogeneous

More information

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,

More information

Introduction ORIGINAL RESEARCH. Xiaogang Li 1,2, Shanmiao Gou 1, Zhiqiang Liu 1, Zeng Ye 1 & Chunyou Wang 1. Open Access. Abstract

Introduction ORIGINAL RESEARCH. Xiaogang Li 1,2, Shanmiao Gou 1, Zhiqiang Liu 1, Zeng Ye 1 & Chunyou Wang 1. Open Access. Abstract Cancer Medicine ORIGINAL RESEARCH Open Access Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology,

More information

Surveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease

Surveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease Ann Surg Oncol (2012) 19:3486 3490 DOI 10.1245/s10434-012-2442-z ORIGINAL ARTICLE ENDOCRINE TUMORS Surveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease Sara E. Murray, MD

More information

Overview on Gastric Cancer

Overview on Gastric Cancer Chapter 1 Gastric neuroendocrine tumors Elife Sahan 1 *; Nusret Erdogan 2 1 Department of Pathology, Taksim s Training and Research Hospital, İstanbul, Turkey 2 Department of Pathology Laboratory Techniques,

More information

Objectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013

Objectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013 Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors Pathology Update 2013 Ozgur Mete, MD Consultant in Endocrine Pathology, Department of Pathology, University Health Network Assistant

More information

Pancreatic Cancer: The ABCs of the AJCC and WHO

Pancreatic Cancer: The ABCs of the AJCC and WHO Pancreatic Cancer: The ABCs of the AJCC and WHO Aatur D. Singhi, MD PhD Assistant Professor University of Pittsburgh Medical Center Department of Pathology singhiad@upmc.edu Case presentation Objectives

More information

NET / GIST / MEN. 2014/2015 FCDS Educational Webcast Series. October 16, Steven Peace, CTR

NET / GIST / MEN. 2014/2015 FCDS Educational Webcast Series. October 16, Steven Peace, CTR NET / GIST / MEN 2014/2015 FCDS Educational Webcast Series October 16, 2014 Steven Peace, CTR Anatomy and Physiology of the (Neuro)Endocrine System WHO Classification, Tumor Grade, Hereditary Syndromes

More information

Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China

Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China Contrast Media & Molecular Imaging, Article ID 234389, 9 pages https://doi.org/1.1155/218/234389 Research Article Clinical and Prognostic Value of PET/CT Imaging with Combination of 68 Ga-DOTATATE and

More information

APPENDIX 5 PATHOLOGY 1. Handling and gross examination of gastrointestinal and pancreatic NETs

APPENDIX 5 PATHOLOGY 1. Handling and gross examination of gastrointestinal and pancreatic NETs APPENDIX 5 PATHOLOGY 1. Handling and gross examination of gastrointestinal and pancreatic NETs Specimen handling and gross examination should be performed according to the Royal College of Pathologists

More information

Neuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam

Neuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam Neuro-endocrine and pancreatic non-adenocarcinomas Marc Engelbrecht, AMC, Amsterdam Pancreatic Tumors q Epithelial Exocrine q Mesenchymal Ductal Adenocarcinoma (85-95%) Metastasis Lymfoma Acinar Cell Carcinoma

More information

3/23/2017. Differentiation: Differentiation: Immunohistochemistry. Well Differentiated vs. Poorly Differentiated Neuroendocrine Neoplasms

3/23/2017. Differentiation: Differentiation: Immunohistochemistry. Well Differentiated vs. Poorly Differentiated Neuroendocrine Neoplasms Disclosure Statement When Immunostains Can Get You Into Trouble (and how they can help you out): Neuroendocrine Neoplasms Arthur Purdy Stout Society March 5, 2017 Dr. Klimstra receives royalty payments

More information

The clinically challenging entity of liver metastasis from tumors of unknown primary

The clinically challenging entity of liver metastasis from tumors of unknown primary The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver

More information

3/22/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships. Grading G1. Grading. Ki67 index V.

3/22/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships. Grading G1. Grading. Ki67 index V. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship

More information

Community Case. Saeed Awan R5

Community Case. Saeed Awan R5 Community Case Saeed Awan R5 18 year old presents to ER with history of pain right lower quadrant for three days. Nauseated, denies vomiting and bowel movements normal and no urinary complaint. Admitted

More information

Lu 177-Dotatate (Lutathera) Therapy Information

Lu 177-Dotatate (Lutathera) Therapy Information Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine

More information

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon

More information

Recent developments of oncology in neuroendocrine tumors (NETs)

Recent developments of oncology in neuroendocrine tumors (NETs) Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in

More information

Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?

Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable? Original Article Page 1 of 5 Neuroendocrine tumors (NETs) of unknown : is early surgical exploration and aggressive debulking justifiable? Yi-Zarn Wang 1, Aman Chauhan 2, Jeffrey Rau 1, Anne E. Diebold

More information

RESEARCH. Resources and Methods

RESEARCH. Resources and Methods The clinical characteristics and prognosis of 73 patients with Nonfunctional Gastroenteropancreatic neuroendocrine neoplasm: a 10-year retrospective study of a single center Gastroenteropancreatic neuroendocrine

More information

BC CRC Update Unusual Colorectal Tumors

BC CRC Update Unusual Colorectal Tumors BC CRC Update Unusual Colorectal Tumors Anthony MacLean, MD, FRCSC, FACS, FASCRS Colorectal Surgeon Foothills Medical Centre Clinical Associate Professor of Surgery and Oncology University of Calgary I

More information

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10): Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE

More information

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm

More information

CT Evaluation of Gastroenteric Neuroendocrine Tumors: Relationship Between CT Features and the Pathologic Classification

CT Evaluation of Gastroenteric Neuroendocrine Tumors: Relationship Between CT Features and the Pathologic Classification Gastrointestinal Imaging Original Research Feng et al. Gastrointestinal Imaging Original Research Shi-Ting Feng 1 Yanji Luo 1 Tao Chan 2 Zhenpeng Peng 1 Jie Chen 3 Minhu Chen 3 Zi-Ping Li 1 Feng ST, Luo

More information

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man

More information

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description

More information

Antiangiogenics are effective treatments in NETs

Antiangiogenics are effective treatments in NETs RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David

More information

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum

More information

3/22/2017. Disclosure of Relevant Financial Relationships. Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017.

3/22/2017. Disclosure of Relevant Financial Relationships. Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017. Disclosure of Relevant Financial Relationships Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017. USCAP requires that all planners (Education Committee) in a position to influence or control

More information

NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante

NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante University of Turin, San Luigi Hospital, Orbassano, Turin, Italy marco.volante@unito.it pure NE tum..a grey zone pure non-ne ca. 0% NE

More information

Pharmacy Prior Authorization Somatostatin Analogs Clinical Guideline

Pharmacy Prior Authorization Somatostatin Analogs Clinical Guideline Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce

More information

Clinical relevance of tumor markers and epidemiology of neuroendocrine tumors Korse, C.M.

Clinical relevance of tumor markers and epidemiology of neuroendocrine tumors Korse, C.M. UvA-DARE (Digital Academic Repository) Clinical relevance of tumor markers and epidemiology of neuroendocrine tumors Korse, C.M. Link to publication Citation for published version (APA): Korse, C. M. (011).

More information

Clinicopathological Characteristics and Prognosis-Related Factors of Resectable Pancreatic Neuroendocrine Tumors

Clinicopathological Characteristics and Prognosis-Related Factors of Resectable Pancreatic Neuroendocrine Tumors ORIGINAL ARTICLE Clinicopathological Characteristics and Prognosis-Related Factors of Resectable Pancreatic Neuroendocrine Tumors A Retrospective Study of 104 Cases in a Single Chinese Center Xu Han, MD,*

More information

Colon and Rectum: 2018 Solid Tumor Rules

Colon and Rectum: 2018 Solid Tumor Rules 2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent

More information

ITALIAN SURGICAL SOCIETY ENDOCRINE SURGERY SCHOOL LIVER METASTASIS FROM NEUROENDOCRINE TUMORS

ITALIAN SURGICAL SOCIETY ENDOCRINE SURGERY SCHOOL LIVER METASTASIS FROM NEUROENDOCRINE TUMORS ITALIAN SURGICAL SOCIETY ENDOCRINE SURGERY SCHOOL LIVER METASTASIS FROM NEUROENDOCRINE TUMORS Gennaro Favia Liver metastasis from NETs Incidence 75% in NETs Knox CD, J Gastroint Surg 2006 .but 28-45% cases

More information

Lung neuroendocrine tumors: pathological characteristics

Lung neuroendocrine tumors: pathological characteristics Review Article Lung neuroendocrine tumors: pathological characteristics Luisella Righi 1, Gaia Gatti 1, Marco Volante 1, Mauro Papotti 2 1 Department of Oncology, San Luigi Hospital, Orbassano, Italy;

More information